Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.41 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.38 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8659117 | 0.89 | LMNA (0.39) | CTSSAPOBEC3AAPOBEC3GCYP1A2SLC6A3 | |
| SCHEMBL8661249 | 0.84 | LMNA (0.43) | CTSSAPOBEC3AAPOBEC3GCYP1A2 | |
| SCHEMBL5744906 | 0.81 | PPARA (0.49) | KLK7KLK5PPARACTSSAPOBEC3A | |
| SCHEMBL8662057 | 0.77 | CA1 (0.39) | CTSSAPOBEC3AAPOBEC3G | |
| SCHEMBL9422665 | 0.77 | CTSS (0.40) | CTSSAPOBEC3AAPOBEC3GCYP1A2 | |
| SCHEMBL9517893 | 0.76 | CA1 (0.38) | CTSSAPOBEC3AAPOBEC3G | |
| SCHEMBL25244453 | 0.76 | POLB (0.37) | APOBEC3AAPOBEC3G | |
| SCHEMBL25243094 | 0.76 | POLB (0.37) | APOBEC3AAPOBEC3G | |
| SCHEMBL25287341 | 0.76 | POLB (0.37) | APOBEC3AAPOBEC3G | |
| SCHEMBL5829155 | 0.75 | PPARA (0.51) | KLK7KLK5PPARACTSSPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1439162-B1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORP (JP) | 2008-03-26 | — | — | EP | disclosed |
| US-6998495-B2 | Method for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2006-02-14 | — | — | US | disclosed |
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | KANEKA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1439162-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 3,5-DIHYDROXYCARBOXYLIC ACID DERIVATIVE | KANEKA CORPORATION (JP) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254392-A1 | Process for producing optically active 3,5-dihydroxycarboxylic acid derivative | HAO2, GRHPR, HDHD5 | KLK7 3735/4885KLK5 3352/4885PPARA 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.